**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 86056

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Comparative detection of syndecan-2 methylation in preoperative and postoperative stool DNA in patients with colorectal cancer**

Song JH *et al*. Perioperative SDC2 methylation in CRC

Ji Hyeong Song, Tae Jeong Oh, Sungwhan An, Kyung Ha Lee, Ji Yeon Kim, Jin Soo Kim

**Ji Hyeong Song, Jin Soo Kim,** Department of Surgery, Chungnam National University Sejong Hospital, Sejong 30099, South Korea

**Tae Jeong Oh, Sungwhan An,** Genomictree, Inc., Daejeon 34027, South Korea

**Kyung Ha Lee, Ji Yeon Kim, Jin Soo Kim,** Department of Surgery, College of Medicine, Chungnam National University, Daejeon 35015, South Korea

**Author contributions:** Song JH collected and analyzed the clinical data, drafted the manuscript, and prepared the figures; Oh TJ and An S drafted the manuscript; Lee KH and Kim JY collected the stool samples; Kim JS participated in study design, collected the stool samples, collected and analyzed the clinical data, drafted the manuscript, and prepared the figures; All authors read and approved the final manuscript.

**Supported by** the Research Fund of Chungnam National University, No. 2018-0626-01.

**Corresponding author: Jin Soo Kim, MD, PhD, Assistant Professor,** Surgery, Chungnam National University Sejong Hospital, 20, Bodeum 7-ro, Sejong-si, Republic of Korea, Sejong 30099, South Korea. jskim7562@gmail.com

**Received:** June 8, 2023

**Revised:** July 13, 2023

**Accepted:** August 4, 2023

**Published online:** September 27, 2023

**Abstract**

BACKGROUND

Early detection of colorectal cancer (CRC) is essential to reduce cancer-related morbidity and mortality. Stool DNA (sDNA) testing is an emerging method for early CRC detection. Syndecan-2 (*SDC2*) methylation is a potential biomarker for the sDNA testing. Aberrant DNA methylation is an early epigenetic event during tumorigenesis and can occur in the normal colonic mucosa during aging, which can compromise the sDNA test results.

AIM

To determine whether methylated *SDC2* in sDNA normalizes after surgical resection of CRC.

METHODS

In this prospective study, we enrolled 151 patients with CRC who underwent curative surgical resection between September 2016 and May 2020. Preoperative stool samples were collected from 123 patients and postoperative samples were collected from 122 patients. A total of 104 samples were collected from both preoperative and postoperative patients. Aberrant promoter methylation of *SDC2* in sDNA was assessed using linear target enrichment quantitative methylation-specific real-time polymerase chain reaction. Clinicopathological parameters were analyzed using the results of *SDC2* methylation.

RESULTS

Detection rates of *SDC2* methylation in the preoperative and postoperative stool samples were 88.6% and 19.7%, respectively. Large tumor size (3 cm, *P* = 0.019) and advanced T stage (T3–T4, *P* = 0.033) were positively associated with the detection rate of *SDC2* methylation before surgery. Female sex was associated with false positives after surgery (*P* = 0.030). Cycle threshold (CT) values were significantly decreased postoperatively compared with preoperative values (*P* < 0.001). The postoperative negative conversion rate for preoperatively methylated *SDC2* was 79.3% (73/92).

CONCLUSION

Our results suggested that the *SDC2* methylation test for sDNA has acceptable sensitivity and specificity. However, small size and early T stage tumors are associated with a low detection rate of *SDC2* methylation. As the cycle threshold values significantly decreased after surgery, *SDC2* methylation test for sDNA might have a diagnostic value for CRC.

**Key Words:** Biomarkers; DNA methylation; Syndecan-2; Colorectal cancer

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Song JH, Oh TJ, An S, Lee KH, Kim JY, Kim JS. Comparative detection of syndecan-2 methylation in preoperative and postoperative stool DNA in patients with colorectal cancer. *World J Gastrointest Surg* 2023; 15(9): 2032-2041

**URL:** https://www.wjgnet.com/1948-9366/full/v15/i9/2032.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v15.i9.2032

**Core Tip:** This prospective study evaluated the detection of syndecan-2 (*SDC2*) methylation in preoperative and postoperative stool DNA samples of colorectal cancer (CRC) patients. The study demonstrated that the *SDC2* methylation test showed high sensitivity (88.6%) for detecting CRC before surgery, indicating its potential as a non-invasive diagnostic tool. Postoperatively, the detection rate decreased to 19.7%, suggesting the normalization of *SDC2* methylation after surgical resection. The study highlights the diagnostic value of *SDC2* methylation in preoperative and postoperative stool samples, supporting its role as a non-invasive screening tool for CRC.

**INTRODUCTION**

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and second leading cause of cancer-related deaths worldwide[1]. According to the 2019 Korean statistics, the prevalence of CRC was the third highest, following thyroid and lung cancer. From 2015 to 2019, the 5-year survival rate of CRC patients in Korea was 74.3%[2]. Patients with metastatic CRC have a 5-year survival rate of < 10%, whereas those with early detection of CRC have a 5-year survival rate of > 90%[3]. Therefore, the early detection of CRC is essential to reduce cancer-related morbidity and mortality.

Most patients with early-stage CRC are mostly asymptomatic. There are several screening tools for detecting asymptomatic CRC. The fecal occult blood test and fecal immunochemical test are non-invasive, inexpensive, and convenient methods. However, these tests have low sensitivity and specificity[4]. Computed tomography colonography can be used as an alternative examination for colonoscopy, which non-invasively examines the entire colon beyond the obstructive. However, there are concerns about radiation hazards and the disadvantage of detecting small polyps < 5mm in size. Colonoscopy is the most accurate method with the advantage of being able to perform procedures such as biopsy and polypectomy. In the NordICC trial, a prospective, multinational, and randomized controlled trial investigating the effectiveness of colonoscopy on CRC incidence and mortality, colonoscopy as a screening tool showed good compliance, a high rate of adenoma yield, and adequate performance[5]. However, colonoscopy is an invasive procedure that requires mechanical bowel preparation and carries the risk of complications, such as perforation or electrolyte imbalance. Therefore, there is a need to develop a non-invasive and highly accurate CRC screening tool, especially for those reluctant to undergo colonoscopy.

CRC carcinogenesis is associated with the accumulation of genetic and epigenetic alterations[6]. Aberrant DNA methylation is one of the most common molecular alterations involved in CRC[7]. Because exfoliated cells from tumors are present in stool samples from CRC patients, detection of aberrant methylation is emerging as a non-invasive diagnostic tool for CRC[8]. Several stool DNA (sDNA)-based methylation markers are available for the early detection of CRC[9,10]. Among these, syndecan-2 (*SDC2*) has been reported as a potential biomarker for sDNA testing[11-13]. Aberrant DNA methylation is an early epigenetic event during tumorigenesis that can occur in the normal colonic mucosa during aging[14], which may compromise the sDNA test results. If preoperatively methylated *SDC2* (me*SDC2*) normalizes after the surgical resection of CRC, it may have diagnostic value and may be used for postoperative surveillance[15]. Therefore, we conducted a prospective observational study to compare *SDC2* methylation in the sDNA of patients with CRC before and after surgery.

**MATERIALS AND METHODS**

***Patients***

In this prospective study, we enrolled 151 patients diagnosed with CRC who underwent surgical resection with curative intent between September 2016 and May 2020 at the Department of Surgery, Chungnam National University Hospital (South Korea). This observational study was approved by the Institutional Review Board of our institute (No. 2016-05-018). The exclusion criteria were as follows: (1) Patients under 18 or over 80 years of age; (2) Difficulty in obtaining informed consent due to mental health issues; (3) Tumor complications such as bleeding, perforation, or obstruction; and (4) Palliative operation. Among the 151 enrolled patients, four dropped out. Two patients were transferred to other hospitals, and two were unresectable. Clinical data were collected for 147 patients. Stool samples were collected from 123 patients preoperatively and 122 patients postoperatively, excluding those due to poor sample quality and inadequate sample amount. A total of 104 samples were collected from both preoperative and postoperative patients. Figure 1 shows the flowchart of the enrolled patients.

***Stool collection, DNA isolation, and bisulfite treatment***

For each subject, at least 2 g of voided stool sample was collected in 20 mL of preservative buffer (Genomictree, Inc., Daejeon, South Korea) using a disposable spatula from four to five different locations. The samples were collected from the patients before and after definitive surgery. Inadequate stool specimens were not included in the methylation analysis (*e.g.*, diarrhea or loose stools).

sDNA was isolated using the GT Nucleic Acid PREP Kit II (Genomictree, Inc., Daejeon, South Korea) according to the manufacturer’s instructions. The Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific, MA, United States) was used to determine the DNA concentration. Briefly, all stool samples were weighed and homogenized in a preservative buffer using a multiple vortex mixer (MIULAB, Hangzhou, China). After homogenization, 1–2 g of each stool sample was used for DNA isolation.

Each two µg of stool-derived genomic DNA was chemically modified with sodium bisulfite using the EZ DNA Methylation-Gold Kit (ZYMO Research, CA, United States) according to the manufacturer’s instructions. Bisulfite-converted DNA was purified using a Zymo-Spin IC column (ZYMO Research) and eluted with 10 µL of distilled water. Bisulfite-converted DNA was either used immediately for methylation analysis or stored at -20 ºC until use.

***Analysis of SDC2 methylation in sDNA using meSDC2 linear target enrichment-quantitative methylation-specific real-time polymerase chain reaction test and data***

The me*SDC2* linear target enrichment (LTE)-quantitative methylation-specific real-time polymerase chain reaction (qMSP)assay was performed in duplicate reactions for each sample as described by Han *et al*[13]. A highly sensitive two-step me*SDC2* LTE-qMSP assay was used to measure *SDC2* methylation in sDNA. First, LTE was used to enrich me*SDC2* target DNA and control *COL2A1* DNA from the bisulfite-modified DNA. The region of the *COL2A1* gene lacking CpG dinucleotides was used as a control to estimate the amount of amplifiable template and the adequacy of bisulfite conversion. The LTE reaction mixture (20 µL) containing 2.0 µg of bisulfite-converted sDNA, 50 nmol/L each of *SDC2* methylation-specific antisense (5′-AAAGATTCGGCGACCACCGAACGACTCAAACTCGAAAACTCG-3’) and *COL2A1* gene-specificantisense primers (5′-AAAGATTCGGCGACCACCGACTAICCCAAAAAAACCCAATCCTA-3′) attached to a 5’ universal sequence (5’-AAAGATTCGGCGACCACCGA-3’), and 4 µL of 5× AptaTaq polymerase chain reaction (PCR) master mix (Roche Diagnostics, Basel, Switzerland) was prepared. The thermal cycling conditions were as follows: 95 °C for 5 min, followed by 35 cycles of 95 °C for 15 s and 60 °C for 60 s. Next, the reaction mixture volume was scaled up to 40 µL, containing 8 µL of 5× AptaTaq PCR master mix, 250 nmol/L *SDC2* methylation-specific sense primer (5′-GTAGAAATTAATAAGTGAGAGGGC-3′), 125 nmol/L *SDC2* probe (5′-FAM-TTCGGGGCGTAGTTGCGGGCGG-3′), 125 nmol/L *COL2A1* sense primer (5′GTAATGTTAGGAGTATTTTGTGGITA-3′), 62.5 nmol/L *COL2A1* probe (5′-Cy5-AGAAGAAGGGAGGGGTGTTAGGAGAGG-3′), and 250 nmol/L universal sequence primer. Thermal cycling conditions were as follows: 95 °C for 5 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. Heating and cooling rates were 20 °C/s and 15 °C/s, respectively. For each run, bisulfite-converted methylated (HCT116) and unmethylated genomic DNA (whole-genome amplified human lymphocyte DNA) were used as methylation controls. Non-template and non-template bisulfite-converted controls were also included in the study.

PCR for *SDC2* and *COL2A1* was performed in a single tube. me*SDC2* LTE-qMSP was performed using Rotor-Gene Q real-time PCR instrument (Qiagen, Hilden, Germany). The cycle threshold (CT) value was calculated using the Rotor-Gene Q software. Lower CT values indicated higher levels of *SDC2* methylation. For PCR analysis, *SDC2* methylation was detected if the CT was less than 40 cycles. It was not detected if CT was not measurable. Samples were categorized as positive if at least one of the two reactions showed detectable *SDC2*, and they were considered negative if *SDC2* methylation was not measurable in both reactions. The test results were acceptable only when the CT value of *COL2A1* was < 31. If *COL2A1* was not detected, or the CT value was > 31, the test was repeated. Neither the personnel involved in laboratory work nor data analysis of the *SDC2* methylation results was informed of colonoscopic findings or pathology outcomes as reference standards. Oh TJ and An S are employees and shareholders of Genomictree, Inc.

***Statistical analysis***

Statistical analysis of the data was performed using IBM SPSS Statistics 26 (SPSS Inc., Chicago, IL, United States). Chi-square and/or Fisher’s exact tests were used for categorical variables. Detection rates were evaluated dichotomously as ‘0’ for methylation-negative and ‘1’ for methylation-positive.

The CT values before and after surgery according to tumor node metastasis (TNM) stage were compared using analysis of variance (ANOVA). A paired *t*-test was performed to compare CT values before and after surgery for each patient. A *P* value < 0.05 was considered statistically significant.

In addition, we retrieved literatures by Reference Citation Analysis to supplement the latest cutting-edge research results.

**RESULTS**

Patient characteristics are described in Table 1. In total, 97 male (66%) and 50 female (34%) patients were included in the preoperative or postoperative sampling. The mean age was 62.3. Total colonoscopy was performed before surgery in 133 patients (90.5%), and remnant advanced adenoma (RAA) was present in 18 patients (12.2%). Among the 18 patients with RAA, five remained *SDC2* methylation-positive after surgery. The recurrence rate was 6.8% in all patients.

***Detection rates of******the******SDC2 methylation test***

Figure 2 shows the detection rates of *SDC2* methylation according to TNM stage. The positivity rate of the *SDC2* methylation test before surgery was 88.6% (109/123), and the false negative rate was 11.4% (14/123). The positivity rates for stages 0, I, II, III, and IV were 75% (3/4), 83.9% (26/31), 91.1% (41/45), 89.2% (33/37), and 100% (6/6), respectively (Figure 2A). The detection rate of *SDC2* methylation after surgery was 19.7% (24/122). The detection rates for stages 0, I, II, III, and IV were 25% (1/4), 31.2% (10/32), 17.5% (7/40), 14.0 (6/43), and 0% (0/3), respectively (Figure 2B). The demographic analysis of patients according to the preoperative and postoperative *SDC2* methylation results is presented in Table 2. Large tumor size (3 cm, *P* = 0.019) and advanced T stage (T3–T4, *P* = 0.033) were associated with positivity of *SDC2* methylation before surgery. Additionally, female patients showed more false positives after surgery (*P* = 0.030).

***CT values of SDC2 methylation***

The distribution of CT values in preoperative and postoperative *SDC2* methylation according to TNM stage is shown in Figure 3. There were no significant differences in the CT values of *SDC2* methylation preoperatively (*P* = 0.901) or postoperatively (*P* = 0.332) according to TNM stage.

Figure 4 shows the CT values of me*SDC2* for each patient before and after surgery. Among the 104 patients from whom stool samples were obtained before and after surgery, 92 patients showed positive results for preoperative *SDC2* methylation. The postoperative negative conversion rate for preoperatively me*SDC2* was 79.3% (73/92). The CT values of *SDC2* methylation significantly decreased postoperatively compared to the preoperative values (*P* < 0.001).

**DISCUSSION**

Various screening tools are used for the early detection of CRC to reduce cancer-related morbidity and mortality. Among the screening tools, colonoscopy is the most accurate method and is considered the gold standard with high sensitivity and specificity. However, colonoscopy is an invasive procedure that requires mechanical bowel preparation and carries the risk of complications, such as perforation or electrolyte imbalance. Hence, it is not yet useful as a mass-screening test[16]. Recently, non-invasive and highly accurate tests using sDNA methylation have been reported[6,7,9,10]. Among the several known sDNA biomarkers, *SDC2* was found to be the most accurate single gene[17]. Therefore, *SDC2* methylation in sDNA has been proposed as a non-invasive mass-screening tool for the early detection of CRC.

Recently, Wang *et al*[18] reported a meta-analysis that evaluated the diagnostic performance of the *SDC2* methylation test for detecting CRC. Twelve studies were included in the meta-analysis, and all articles were retrospective studies. Among them, seven studies measured me*SDC2* in sDNA, and five studies measured it in blood. The overall sensitivity was 80% and the specificity was 95%; and the sensitivity and specificity of sDNA test were 83% and 94%, respectively. In the present study, the detection rates of *SDC2* methylation in preoperative and postoperative were 88.6% and 19.7%, respectively. These values represent a sensitivity of 88.6% (109/123, 95%CI: 82%–96%) and specificity of 80.3% (98/122, 95%CI: 72%–87%), and the results were comparable to those of several previous studies.

Zhao *et al*[19] reported the detection rate of me*SDC2* in stool samples from 94 patients with CRC and 124 normal healthy individuals. There were no significant differences in the detection rates of me*SDC2* based on the age, sex, or stage. As the tumor size increased, the positive detection rate of meS*DC2* also increased (*P* < 0.05). Similarly, we found that a large preoperative tumor size and advanced T stage were associated with high detection rates of *SDC2* methylation. Females showed more false positive results after surgery. This result was thought to be due to the small sample size. The combination of *SDC2* with other biomarkers may improve CRC detection rates[9,19].

Several studies have reported that *SDC2* methylation is not related to the clinical stage[11,13,18]. The present study also showed similar results. There was no association between the detection rate of *SDC2* methylation and clinical stage. Although there was no statistically significant difference, the detection rate of *SDC2* methylation according to stage showed a gradual increase. Moreover, Oh *et al*[12] found that the sensitivity of *SDC2* methylation test tended to gradually increase with an increase in the stage. Further studies are needed to validate whether clinical stage affects the detection rate of me*SDC2*.

Few studies have compared sDNA test results before and after surgery. Kisiel *et al*[15] evaluated sDNA markers (*NDRG4* and *BMP3*) in 22 patients with CRC before and after surgery. They demonstrated that methylated sDNA markers present in patients normalized following surgical resection. Nishioka *et al*[20] compared the preoperative and postoperative sDNA levels of 54 patients with CRC who underwent surgical resection. Aberrant methylation of sDNA markers (*CDH4* and *GATA5*) was detected in 23 (42.3%) preoperative stool samples from patients with CRC. Methylated alleles of these genes were not found in the postoperative sDNA. To the best of our knowledge, no studies have compared me*SDC2* levels before and after surgery. We compared the preoperative and postoperative CT values of me*SDC2* in 92 patients who tested positive for *SDC2* methylation before surgery. The CT values of *SDC2* methylation in sDNA were significantly decreased postoperatively compared to the preoperative values. These results indicate that *SDC2* methylation test has diagnostic value and may be used for surveillance.

In our study, twenty-four (19.7%) patients with CRC remained positive for me*SDC2* in the sDNA after surgical resection. Among these patients, there was no recurrence after surgery during the median follow-up period of 46 (1–67) months. Since molecular-level methylation precedes phenotypic tumorigenesis, these patients require follow-up with concern for possible recurrence. However, six patients who experienced recurrence after surgery showed negative results for *SDC2* methylation. The correlation between postoperative *SDC2* methylation and recurrence was not statistically significant (*P* = 0.597). Therefore, based on these results, the present study seemed unlikely to show the usefulness of me*SDC2* in the sDNA as surveillance after CRC surgery. In addition, the liver and peritoneum are the most common sites for CRC metastasis[21], with rare occurrences in other parts of the body[22]. These recurrent cases of metastasis are difficult to detect with a sDNA test, making it difficult to use stool tests as a surveillance tool.

Similar to stool DNA testing, dysbiosis in the microbiota can be used as a test for early detection of CRC by obtaining fecal samples[23]. Several microbial species, such as *F. nucleatum*, *B. fragilis*, and *F. Prausnitzii*, are known to act as a driving force in the occurrence of CRC. Hence, detecting these microbial species in stool samples can aid in the early identification of CRC[24]. Non-invasive fecal biomarkers, such as aberrant methylation of sDNA tests or dysbiosis in the microbiota, can be expected to make important contributions to the early diagnosis and therapeutic implications of CRC in the future.

The present study had several limitations. First, selection bias may have existed because this study was conducted at a single institution with a small sample size. Second, it is insufficient to determine its value as a surveillance tool because *SDC2* methylation was only compared before and after surgery, without long-term follow-up. Therefore, multicenter prospective studies with long-term follow-up are necessary to assess the feasibility of surveillance.

**CONCLUSION**

We demonstrated that the *SDC2* methylation test in sDNA has acceptable sensitivity and specificity. However, small-size and early T stage tumors are associated with a low detection rate of *SDC2* methylation. As the CT values significantly decrease after surgery, *SDC2* methylation of the sDNA test exhibits diagnostic value for CRC.

**ARTICLE HIGHLIGHTS**

***Research background***

Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide, emphasizing the need for early detection. Stool DNA (sDNA) testing is a promising non-invasive method for CRC detection, and syndecan-2 (*SDC2*) methylation has been identified as a potential biomarker for this test.

***Research motivation***

The study aimed to investigate whether *SDC2* methylation in sDNA normalizes after surgical resection of CRC, which could have implications for the diagnostic value and postoperative surveillance of *SDC2* methylation.

***Research objectives***

The study aimed to compare the detection rates of *SDC2* methylation in preoperative and postoperative stool samples of CRC patients and assess the association between *SDC2* methylation and clinicopathological parameters. The study also sought to evaluate the change in *SDC2* methylation levels before and after surgery.

***Research methods***

A prospective study enrolled 151 CRC patients who underwent surgical resection. Stool samples were collected before and after surgery, and *SDC2* methylation in sDNA was assessed using a quantitative methylation-specific real-time polymerase chain reaction. The association between *SDC2* methylation and clinicopathological parameters was analyzed.

***Research results***

The detection rate of *SDC2* methylation was significantly higher in preoperative stool samples (88.6%) compared to postoperative samples (19.7%). Large tumor size and advanced T stage were associated with higher detection rates before surgery, while female sex was associated with false positives after surgery. The cycle threshold (CT) values significantly decreased after surgery, indicating a normalization of *SDC2* methylation. The postoperative negative conversion rate for preoperatively methylated *SDC2* was 79.3%.

***Research conclusions***

The study findings suggest that the *SDC2* methylation test in sDNA has acceptable sensitivity and specificity for CRC detection. However, the detection rate is lower for small-size and early T stage tumors. The significant decrease in CT values after surgery indicates the diagnostic value of *SDC2* methylation testing for CRC.

***Research perspectives***

Further research is needed to validate the findings and assess the long-term utility of *SDC2* methylation testing as a surveillance tool for postoperative CRC patients. Multicenter prospective studies with extended follow-up periods are warranted to evaluate the feasibility and effectiveness of *SDC2* methylation testing in clinical practice.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 Korean statistics 2019. [cited 2023 Jun 8]. Korean Statistical Information Service [Internet]. Available from: https://kosis.kr/

3 **Dashwood RH**. Early detection and prevention of colorectal cancer (review). *Oncol Rep* 1999; **6**: 277-281 [PMID: 10022989 DOI: 10.3892/or.6.2.277]

4 **Morikawa T**, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. *Gastroenterology* 2005; **129**: 422-428 [PMID: 16083699 DOI: 10.1053/j.gastro.2005.05.056]

5 **Bretthauer M**, Kaminski MF, Løberg M, Zauber AG, Regula J, Kuipers EJ, Hernán MA, McFadden E, Sunde A, Kalager M, Dekker E, Lansdorp-Vogelaar I, Garborg K, Rupinski M, Spaander MC, Bugajski M, Høie O, Stefansson T, Hoff G, Adami HO; Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group. Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial. *JAMA Intern Med* 2016; **176**: 894-902 [PMID: 27214731 DOI: 10.1001/jamainternmed.2016.0960]

6 **Berger BM**, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. *Pathology* 2012; **44**: 80-88 [PMID: 22198259 DOI: 10.1097/PAT.0b013e3283502fdf]

7 **Kadiyska T**, Nossikoff A. Stool DNA methylation assays in colorectal cancer screening. *World J Gastroenterol* 2015; **21**: 10057-10061 [PMID: 26401070 DOI: 10.3748/wjg.v21.i35.10057]

8 **Vedeld HM**, Goel A, Lind GE. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. *Semin Cancer Biol* 2018; **51**: 36-49 [PMID: 29253542 DOI: 10.1016/j.semcancer.2017.12.004]

9 **Chen J**, Sun H, Tang W, Zhou L, Xie X, Qu Z, Chen M, Wang S, Yang T, Dai Y, Wang Y, Gao T, Zhou Q, Song Z, Liao M, Liu W. DNA methylation biomarkers in stool for early screening of colorectal cancer. *J Cancer* 2019; **10**: 5264-5271 [PMID: 31602277 DOI: 10.7150/jca.34944]

10 **Imperiale TF**, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med* 2014; **370**: 1287-1297 [PMID: 24645800 DOI: 10.1056/NEJMoa1311194]

11 **Niu F**, Wen J, Fu X, Li C, Zhao R, Wu S, Yu H, Liu X, Zhao X, Liu S, Wang X, Wang J, Zou H. Stool DNA Test of Methylated Syndecan-2 for the Early Detection of Colorectal Neoplasia. *Cancer Epidemiol Biomarkers Prev* 2017; **26**: 1411-1419 [PMID: 28619831 DOI: 10.1158/1055-9965.EPI-17-0153]

12 **Oh TJ**, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. *Clin Epigenetics* 2017; **9**: 126 [PMID: 29225717 DOI: 10.1186/s13148-017-0426-3]

13 **Han YD**, Oh TJ, Chung TH, Jang HW, Kim YN, An S, Kim NK. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. *Clin Epigenetics* 2019; **11**: 51 [PMID: 30876480 DOI: 10.1186/s13148-019-0642-0]

14 **Toyota M**, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci U S A* 1999; **96**: 8681-8686 [PMID: 10411935 DOI: 10.1073/pnas.96.15.8681]

15 **Kisiel JB**, Yab TC, Taylor WR, Mahoney DW, Ahlquist DA. Stool methylated DNA markers decrease following colorectal cancer resection--implications for surveillance. *Dig Dis Sci* 2014; **59**: 1764-1767 [PMID: 24993691 DOI: 10.1007/s10620-014-3265-5]

16 **Ransohoff DF**. How much does colonoscopy reduce colon cancer mortality? *Ann Intern Med* 2009; **150**: 50-52 [PMID: 19075200 DOI: 10.7326/0003-4819-150-1-200901060-00308]

17 **Gachabayov M**, Lebovics E, Rojas A, Felsenreich DM, Latifi R, Bergamaschi R. Performance evaluation of stool DNA methylation tests in colorectal cancer screening: a systematic review and meta-analysis. *Colorectal Dis* 2021; **23**: 1030-1042 [PMID: 33410272 DOI: 10.1111/codi.15521]

18 **Wang L**, Liu Y, Zhang D, Xiong X, Hao T, Zhong L, Zhao Y. Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening: a meta-analysis. *BMC Gastroenterol* 2022; **22**: 314 [PMID: 35754025 DOI: 10.1186/s12876-022-02395-7]

19 **Zhao G**, Liu X, Liu Y, Li H, Ma Y, Li S, Zhu Y, Miao J, Xiong S, Fei S, Zheng M. Aberrant DNA Methylation of SEPT9 and SDC2 in Stool Specimens as an Integrated Biomarker for Colorectal Cancer Early Detection. *Front Genet* 2020; **11**: 643 [PMID: 32625237 DOI: 10.3389/fgene.2020.00643]

20 **Nishioka Y**, Ueki T, Hokazono K, Nagayoshi K, Tanaka M. Comparative detection of aberrantly methylated DNA in preoperative and postoperative stool from patients with colorectal cancers. *Int J Biol Markers* 2015; **30**: e81-e87 [PMID: 24980446 DOI: 10.5301/jbm.5000099]

21 **Pretzsch E**, Bösch F, Neumann J, Ganschow P, Bazhin A, Guba M, Werner J, Angele M. Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread. *J Oncol* 2019; **2019**: 7407190 [PMID: 31641356 DOI: 10.1155/2019/7407190]

22 **Lucke-Wold B**, Bonasso PC, Cassim R. Primary colon adenocarcinoma with metastatic disease to the rectum followed by the left axilla. *Am Med Stud Res J* 2017; **4**: 57-61 [PMID: 28393107 DOI: 10.15422/amsrj.2017.03.009]

23 **Villéger R**, Lopès A, Veziant J, Gagnière J, Barnich N, Billard E, Boucher D, Bonnet M. Microbial markers in colorectal cancer detection and/or prognosis. *World J Gastroenterol* 2018; **24**: 2327-2347 [PMID: 29904241 DOI: 10.3748/wjg.v24.i22.2327]

24 **Abdulla MH**, Agarwal D, Singh JK, Traiki TB, Pandey MK, Ahmad R, Srivastava SK. Association of the microbiome with colorectal cancer development (Review). *Int J Oncol* 2021; **58** [PMID: 33760154 DOI: 10.3892/ijo.2021.5197]

**Footnotes**

**Institutional review board statement:** This observational study was approved by the Institutional Review Board of our institute (IRB No. 2016-05-018).

**Informed consent statement:** Written informed consent was obtained from all subjects.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 8, 2023

**First decision:** July 7, 2023

**Article in press:** August 4, 2023

**Specialty type:** Surgery

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kisiel JB, United States; Lucke-Wold B, United States **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Cai YX

**Figure Legends**

****

**Figure 1 Flowchart of preoperative and postoperative sample collection in patients with colorectal cancer.**

****

**Figure 2 Percentages of syndecan-2 methylation test results according to tumor node metastasis stage.** Using the 1/2 algorithm, the percentage of samples with detectable methylated syndecan-2is presented by bars. A: Preoperative stool samples were collected from 123 patients. Overall sensitivity was 88.6%; B: Postoperative stool samples were collected from 122 patients. Overall specificity was 80.3%. *SDC2*: Syndecan-2; TNM: Tumor node metastasis.

****

**Figure 3 Distribution of syndecan-2 methylation according to tumor node metastasis stage.** The cycle threshold (CT) values for each sample were calculated as 40-CT. A higher 40-CT indicates a higher methylation level of syndecan-2 (*SDC2*). If *SDC2* methylation was not detected, it was expressed as 0. A: Preoperative (*n* = 123); B: Postoperative (*n* = 122). *SDC2*: Syndecan-2; CT: Cycle threshold; TNM: Tumor node metastasis.

****

**Figure 4 Paired cycle threshold values of syndecan-2 methylation before and after surgery for each patient (*n* = 104).** The cycle threshold (CT) values were calculated as 40-CT. A higher 40-CT indicated a higher methylation level of syndecan-2 (*SDC2*). If *SDC2* methylation was not detected, it was expressed as 0. *P* value was calculated using a paired *t*-test. *SDC2*: Syndecan-2; CT: Cycle threshold.

**Table 1 Characteristics of patients**

|  |  |  |
| --- | --- | --- |
|  | **Patients with preoperative or postoperative stool sampling, *n* = 147 (%)** | **Patients with preoperative and postoperative stool sampling, *n* = 104 (%)** |
| Sex |  |  |
| Male | 97 (66.0) | 66 (63.5) |
| Female | 50 (34.0) | 38 (36.5)  |
| Age, yr  |  |  |
| Mean (range) | 62.3 (35-80) | 62.8 (35-80) |
| Tumor location |  |  |
| Right colon | 45 (30.6) | 29 (27.9) |
| Left colon | 62 (42.2) | 51 (49.0) |
| Rectum | 40 (27.2) | 24 (23.1) |
| Histology |  |  |
| WD | 6 (4.1) | 4 (3.8) |
| MD | 132 (89.8) | 94 (90.4) |
| PD | 9 (3.4) | 5 (4.8) |
| Mucinous | 4 (2.7) | 1 (1.0) |
| Tumor size, cm |  |  |
| Mean (range) | 3.7 (0.0-15.0) | 3.5 (0.0-9.0) |
| T stage |  |  |
| Tis | 5 (3.4) | 4 (3.8) |
| T1 | 22 (15.0) | 15 (14.4) |
| T2 | 27 (18.4) | 19 (18.3) |
| T3 | 74 (50.3) | 52 (50.0) |
| T4 | 19 (12.9) | 14 (13.5) |
| N stage |  |  |
| N0 | 93 (63.3) | 66 (63.5) |
| N+ | 54 (36.7) | 38 (36.5) |
| TCF before surgery |  |  |
| Not done | 14 (9.5) | 9 (8.7) |
| Done | 133 (90.5) | 95 (91.3) |
| RAA |  |  |
| Not present | 129 (87.8) | 90 (86.5) |
| Present | 18 (12.2) | 14 (13.5) |
| Recurrence |  |  |
| No | 137 (93.2) | 98 (94.2) |
| Yes | 10 (6.8) | 6 (5.8) |

WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated; TCF: Total colonoscopy; RAA: Remnant advanced adenoma.

**Table 2 Demographic analysis of patients according to preoperative and postoperative syndecan-2 methylation test**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **Preoperative (*n* = 123)** | **Postoperative (*n* = 122)** |
| **Negative, *n* = 14 (%)** | **Positive, *n* = 109 (%)** | ***P* value** | **Negative, *n* = 98 (%)** | **Positive *n* = 24 (%)** | ***P* value** |
| Sex |  |  | 0.375 |  |  | 0.030 |
| Male | 11 (78.6) | 69 (63.3) |  | 68 (69.4) | 11 (45.8) |  |
| Female | 3 (21.4) | 40 (36.7) |  | 30 (30.6) | 13 (54.2) |  |
| Age, yr |  |  | 0.512 |  |  | 0.845 |
| < 65 | 9 (64.3) | 60 (55.0) |  | 55 (56.1) | 14 (58.3) |  |
| ≥ 65 | 5 (35.7) | 49 (45.0) |  | 43 (43.9) | 10 (41.7) |  |
| Location |  |  | 0.664 |  |  | 0.079 |
| Right colon | 5 (35.7) | 30 (27.5) |  | 34 (34.7) | 3 (12.5) |  |
| Left colon | 7 (50.0) | 51 (46.8) |  | 42 (42.9) | 12 (50.0) |  |
| Rectum | 2 (14.3) | 28 (25.7) |  | 22 (22.4) | 9 (37.5) |  |
| Histology |  |  | 0.226 |  |  | 1.000 |
| WD/MD | 12 (85.7) | 103 (94.5) |  | 92 (93.9) | 23 (95.8) |  |
| PD/Mucinous | 2 (14.3) | 6 (5.5) |  | 6 (6.1) | 1 (4.2) |  |
| Tumor size, cm |  |  | 0.019 |  |  | 0.145 |
| < 3 | 10 (71.4) | 42 (38.5) |  | 41 (41.8) | 14 (58.3) |  |
| ≥ 3 | 4 (28.6) | 67 (61.5) |  | 57 (58.2) | 10 (41.7) |  |
| T stage |  |  | 0.033 |  |  | 0.137 |
| Tis-T2 | 9 (64.3) | 34 (31.2) |  | 33 (33.7) | 12 (50.0) |  |
| T3-T4 | 5 (35.7) | 75 (68.8) |  | 65 (66.3) | 12 (50.0) |  |
| N stage |  |  | 0.769 |  |  | 0.152 |
| N0 | 10 (71.4) | 70 (64.2) |  | 58 (59.2) | 18 (75.0) |  |
| N+ | 4 (28.6) | 39 (35.8) |  | 40 (40.8) | 6 (25.0) |  |
| TNM stage |  |  | 0.769 |  |  | 0.152 |
| 0-II | 10 (71.4) | 70 (64.2) |  | 58 (59.2) | 18 (75.0) |  |
| III-IV | 4 (28.6) | 39 (35.8) |  | 40 (40.8) | 6 (25.0) |  |
| TCF before surgery |  |  | 0.627 |  |  | 0.685 |
| Not done | 2 (14.3) | 10 (9.2) |  | 9 (9.2) | 1 (4.2) |  |
| Done | 12 (85.7) | 99 (90.8) |  | 89 (90.8) | 23 (95.8) |  |
| RAA |  |  | 0.692 |  |  | 0.172 |
| Not present | 13 (92.9) | 94 (86.2) |  | 88 (89.8) | 19 (79.2) |  |
| Present | 1 (7.1) | 15 (13.8) |  | 10 (10.2) | 5 (20.8) |  |

*SDC2*: Syndecan-2; WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated; TCF: Total colonoscopy; RAA: Remnant advanced adenoma.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**